Preventing SARS-CoV-2 infection and its severe outcomes in HIV-infected people
- PMID: 37395252
- PMCID: PMC10328431
- DOI: 10.1097/QAD.0000000000003608
Preventing SARS-CoV-2 infection and its severe outcomes in HIV-infected people
Conflict of interest statement
There are no conflicts of interest.
Comment on
-
No association between use of tenofovir disoproxil fumarate, etravirine, or integrase-strand transfer inhibitors and acquisition or severe outcomes of SARS-CoV-2 infection in people with HIV in the Netherlands.AIDS. 2023 Jul 15;37(9):1481-1486. doi: 10.1097/QAD.0000000000003577. Epub 2023 Apr 13. AIDS. 2023. PMID: 37395254 Free PMC article.
References
-
- Verburgh ML, van der Valk M, Rijnders BJA, Reiss P, Wit FWNM. No association between use of tenofovir disoproxil fumarate, etravirine, or integrase-strand transfer inhibitors and acquisition or severe outcomes of SARS-CoV-2 infection in people with HIV in the Netherlands. AIDS 2023; 37:1481–1486. - PMC - PubMed
-
- Kolata G. FDA approves AZT. Science 1987; 235:1570. - PubMed
-
- Fischl MA, Richman DD, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, et al. . The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med 1987; 317:185–191. - PubMed
-
- Broder S, Mitsuya H, Yarchoan R, Pavlakis GN. NIH conference. Antiretroviral therapy in AIDS. Ann Intern Med 1990; 113:604–618. - PubMed
-
- García-Deltoro M. Rapid initiation of antiretroviral therapy after HIV diagnosis. AIDS Rev 2019; 21:55–64. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous